Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 9
Submit an article Journal homepage
155
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only

Christophe NicolService d'Hématologie, Institut de Cancéro-Hématologie, Hôpital Morvan, CHRU de Brest, Brest Cedex, France;
,
Chloé HenryService d'Onco-Pédiatrie, Hôpital Morvan, CHRU de Brest, Brest Cedex, France;
,
Marie-Anne CouturierService d'Hématologie, Institut de Cancéro-Hématologie, Hôpital Morvan, CHRU de Brest, Brest Cedex, France;
,
Pascal DelépineEtablissement Français du Sang, Site de Brest, CHRU de Brest, Brest Cedex, France;
,
Céline TripogneyEtablissement Français du Sang, Site de Brest, CHRU de Brest, Brest Cedex, France;
,
Caroline BuorsLaboratoire d'Hématologie, Hôpital de la Cavale Blanche, CHRU de Brest, Brest Cedex, France
,
Gaëlle GuillermService d'Hématologie, Institut de Cancéro-Hématologie, Hôpital Morvan, CHRU de Brest, Brest Cedex, France;
,
Christian BerthouService d'Hématologie, Institut de Cancéro-Hématologie, Hôpital Morvan, CHRU de Brest, Brest Cedex, France;
,
Adrian TempesculService d'Hématologie, Institut de Cancéro-Hématologie, Hôpital Morvan, CHRU de Brest, Brest Cedex, France;
&
Jean-Christophe IanottoService d'Hématologie, Institut de Cancéro-Hématologie, Hôpital Morvan, CHRU de Brest, Brest Cedex, France; Correspondence[email protected]
 show all
Pages 2258-2260 | Received 14 Sep 2016, Accepted 16 Jan 2017, Published online: 07 Feb 2017

References

  • Sörgel F, Lerch H, Lauber T. Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. BioDrugs. 2010;24:347–357.
  • Gascon P. The evolving role of biosimilars in haematology-oncology: a practical perspective. Ther Adv Hematol. 2015;6:267–281.
  • Abraham I, Tharmarajah S, MacDonald K. Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. Expert Opin Drug Safety. 2013;12:235–246.
  • Shaw BE, Confer DL, Hwang WY, et al. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica. 2011;96:942–947.
  • Weise M, Kurki P, Wolff-Holz E, et al. Biosimilars: the science of extrapolation. Blood. 2014;124:3191–3196.
  • Ferro HH, Juni M, Bello R, et al. Utilization study of filgrastim (Neutromax) during autologous haematopoietic precursor transplantation for myeloma and lymphoma patients. Transfus Apher Sci. 2009;41:87–93.
  • Ianotto JC, Ngo Sack F, Couturier MA, et al. Biosimilars of filgrastim in ASCT: reduction in G-CSF costs, but similar effects on bone marrow recovery. Leuk Lymphoma. 2014;55:74–77.
  • Pham T, Patil S, Fleming S, et al. Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation. Transfusion. 2015;55:2709–2713.
  • Reményi P, Gopcsa L, Marton I, et al. Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF. Adv Ther. 2014;31:451–460.
  • Ianotto JC, Tempescul A, Yan X, et al. Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients. Bone Marrow Transplant. 2012;47:874–876.
  • Colombat P, Biron P, Laporte JP, et al. BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas. Eur J Cancer. 1990;26:858.
  • Barlogie B, Hall R, Zander A, et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma . Blood. 1986;67:1298–1301.
  • EMA December 2014. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues.
  • Lefrère F, Brignier AC, Elie C, et al. First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor. Adv Therapy. 2011;28:304–310.
  • Publicover AL, Richardson DS, Davies A, et al. Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. Br J Haematol. 2013;162:107–111.
  • Piñana JL, Montesinos P, Martino R, et al. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. Ann Hematol. 2014;93:299–307.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.